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1. Introduction 
Tuberculosis (TB) was initially described during the fifth century B.C. by Hippocrates who 
reported patients with “consumption” (the Greek term is phthisis), a term used to describe 
wasting associated with chest pain, coughing and blood in the sputum. Since then it remains 
a devastating disease with more than 9 million new cases and over 1 million related deaths 
among human immunodeficiency syndrome (HIV) negative populations every year (Smith, 
2003; Yasar et al., 2011). Mycobacterium tuberculosis complex, the causative agent of human 
TB is the most common pathogen of both pulmonary and non pulmonary tuberculosis cases, 
nevertheless as a result of their association with HIV infections nontuberculous Mycobacteria 
(NTM) species are encountered with increasing frequency. While pulmonary disease is the 
most common manifestation of TB, the involvement of the central nervous system (CNS) 
and associated tuberculous meningitis (TBM) represents its most severe form (Christensen 
et al., 2011; Puccioni-Sohler & Brandão, 2007; Venkataswamy et al., 2007). The case fatality 
rate of untreated TBM is almost 100% and a delay in treatment may lead to permanent 
neurological damage, therefore prompt diagnosis is needed for the timely initiation of 
antituberculous therapy in order to prevent secondary complications (Chandramuki et al., 
2002). TBM may also involve children with the peak incidence during the first 4 years of life 
(van Well et al., 2009; Haldar et al., 2009). 
2. Causative agents of tuberculous meningitis 
Mycobacteria are aerobic, nonmotile, gram-positive rods ranging in appearance from 
spherical to short filaments, which may be branched. Their cell wall contains lipids, 
peptidoglycans, and arabinomannans. One distinct characteristic is their ability to retain 
dyes that are usually removed from other microorganisms by alcohols and dilute solutions 
of strong mineral acids such as hydrochloric acid. This ability is attributed to a waxlike layer 
composed of mycolic acids in their cell wall. As a result, they are termed acid-fast bacilli 
(AFB) after Ziehl-Neelsen (ZN) staining (Panicker et al., 2010; Rajni et al., 2011). The 
causative agents of TBM are mainly the members of M. tuberculosis complex and less 
commonly NTM. The incidence of CNS infection due to the latter has increased 
substantially since the onset of the HIV epidemic (Lai et al., 2008; Puccioni-Sohler & 
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Brandão, 2007). According to literature, although the NTM species involved in 
theaetiopathogenesis of meningitis include all four groups of the Runyon classification, 
those more commonly encountered are the Mycobacterium avium complex (MAC), 
Mycobacterium kansasii, M. bovis, M. abscessus, M. fortuitum and Mycobacterium 
nonchromogenicum, the latter being a nonpigmented, slow growing organism which belongs 
to Runyon group III and a part of the Mycobacterium terrae complex. It is reported that M. 
avium complex remains the most common organism causing systemic opportunistic 
bacterial infections in patients with HIV infection, carrying a higher mortality rate despite 
appropriate treatment, while M. kansasii meningitis is similar to M. tuberculosis meningitis. 
Therefore, when NTM are isolated in culture of cerebrospinal fluid (CSF), they should not 
routinely be dismissed as contaminants but considered a significant finding (Cegielski & 
Wallace, 1997; Flor et al., 1996; Jacob et al., 1993; Koirala, 2001; Lai et al., 2008; Maniu et al., 
2001; Mayo et al., 1998; Puccioni-Sohler & Brandão, 2007; Wu et al., 2000).  
3. Epidemiology 
Tuberculosis of the central nervous system is the most severe manifestation of 
extrapulmonary TB and constitutes approximately 1% of all new cases annually, with TBM 
being the commonest form of the disease (Christensen et al., 2011). Several studies have 
attempted to assess its epidemiology with variable conclusions as the disease’s incidence 
and mortality rates differ from country to country according to their individual 
socioeconomic and public health statuses. Mortality rates for instance have been described 
to range from 7 – 40% in developed countries, while the percentages from TB endemic 
countries as well as countries with high HIV prevalence have been found to be significantly 
higher, reaching a 69% in South Africa (Karstaedt et al., 1998; Kent et al., 1993). The key 
point in understanding the epidemiological pattern of the disease is the fact that TBM and 
tuberculosis infection are closely related in this aspect, so that it is generally accepted that 
occurrence of the former in a community is correlated with incidence of the latter and vice 
versa (Chakraborty, 2000). It is therefore considered safe to assume that at a global level 
these two entities share a common trend. According to the latest available data, in 2009 the 
global incidence of TB was 9.4 million cases which is equivalent to 137 cases per 100 000 
population with most of them occurring in Asia and Africa and a smaller proportion 
occurring in Europe and the Region of the Americas. Developing countries in particular 
account for more than 80% of the active cases in the world. The global incidence rate after an 
initial fall during the 20th century rose due to the HIV epidemic with a peak in 2004 and a 
subsequent slow but steady decline that also involves the absolute number of TB related 
deaths. This impact of HIV on TB has accordingly influenced the pattern of TBM’s incidence 
rates (Dye et al., 2009; Varaine et al., 2010; World Health Organization [WHO], 2010). In fact, 
HIV infection constitutes the most important determinant for the development of TBM 
followed by age. As far as the latter is concerned it is in turn determined by the 
socioeconomic status of a certain population. Therefore in populations with a low TB 
prevalence adults seem to be more affected than children. This is reversed in populations 
with a higher TB prevalence. Concerning childhood disease, TBM appears to affect mainly 
children under the age of 5 years with the mean age ranging from 23 to 49 months and 
according to literature close contact with a confirmed case of pulmonary tuberculosis is 
usually the culprit (van Well et al., 2009). 
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4. Pathophysiology 
Since the first description of the disease in 1936 there has been undisputable progress in the 
understanding of the pathogenesis of TBM, with further ongoing research in the field. 
Nevertheless, the exact mechanism of establishment of this uncommon yet devastating 
manifestation of tuberculosis has not been fully elucidated. The disease develops as a result 
of a new infection or of reactivation of a latent one, but in both cases it constitutes a 
disseminated form of a primary extrameningeal focus rather than a primary localization of 
the tuberculous infection. According to recent evidence certain strains seem to be more 
capable of dissemination and might be more predominant in the development of CNS 
disease with the exact mechanisms of neurovirulence being uncertain (Arvanitakis et al., 
1998; Nicolic, 1996). In this direction, studies have demonstrated the possible influence of 
the M. tuberculosis genotype in association with the host’s genetic polymorphisms on the 
disease phenotype as different mycobacterial genotypes seem to induce separate patterns of 
host immune response (Dormans et al., 2004; Manca et al., 2004; Reed et al., 2004). For 
instance, there is evidence that some strains of M. tuberculosis commonly found in Europe 
and America are less likely to cause tuberculous meningitis in Vietnamese adults than 
strains predominantly found in Asia (Caws et al., 2008). The pathogenesis of TBM at a 
cellular level is incompletely understood. According to modern concepts the triad of 
macrophages, T helper lymphocytes and the host plays a central role and through 
interactions of its components the produced Ǆ-interferon, interleukin 1-ǃ and tumour 
necrosis factor promote granuloma formation in a manner similar to pulmonary disease. On 
a macroscopic level it is evident that the development of TBM is a two- step process, the 
onset of which is the entrance of the bacilli into the host with subsequent lung invasion and 
regional lymph node dissemination leading to the primary complex formation. In case of 
central nervous system involvement the characteristic lesions known as Rich’s foci, first 
described in the early 1930s, which represent tuberculous subpial or subependymal foci 
about 1 mm in diameter, are formed through spread of the bacilli to the meninges or brain 
parenchyma (Be et al., 2009; Drevets at al., 2004). Although it is unclear whether M. 
tuberculosis crosses the blood brain barrier as an extra-cellular organism or via infected 
phagocytes (Chackerian et al., 2002), the spread takes place haematogenously. This transport 
occurs either during the short stage of bacteremia that accompanies the primary complex 
formation or as a result of a more prolonged bacteremia in those cases in which the primary 
compex fails to heal and which account for the 10% of all cases. If miliary TB develops, 
dissemination to the CNS is more probable and seems to be particularly involved in the 
pathogenesis of TBM in childhood (Donald et al., 2005). The infrequent possibility of direct 
spread from a site of tuberculous otitis or calvarial osteitis also exists. When mycobacteria 
are deposited in large numbers as part of primary tuberculosis in infants or young children, 
they form the characteristic lesions and cause TBM usually within six months of primary 
infection (Garg, 1999; Prince, 2002). However, in adults and older children deposited 
mycobacteria may not elicit any immune response and may cause latent disease until 
immune recognition or reactivation causes formation of the CNS lesions. The second step of 
the process involves the rupture of a Rich’s focus and the release of bacilli into the 
subarachnoid space giving rise to a T cell dependent granulomatous inflammatory response 
resulting in the development of tuberculous meningitis (Burns, 1997). This inflammatory 
reaction can lead to adhesion formation due to the cell and fibrin rich basal meningeal 
exudates, to obliterative vasculitis mainly affecting the internal carotid artery, proximal 
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middle cerebral artery and perforating vessels of the basal ganglia, or may even extend into 
the parenchyma leading to encephalitis. If the adhesions compromise the interpendicular 
fossa, cranial nerves (mainly II, IV and VI) are affected while in case of obstruction of the 
basal cisterns, the outflow of the forth ventricle or the cerebral aqueduct, hydrocephalus 
develops, the presence of which has been associated with poor prognosis and therapeutic 
failure (Lu et al., 2001). Vasculitis and parenchymal involvement lead to infarctions (most often 
involving the distribution of the middle cerebral artery and striate arteries) and encephalitis 
respectively, which account for the majority of the neurological deficits of the disease. Another 
entity of tuberculous meningitis is that affecting the spinal cord. Spinal meningitis can either 
develop due to direct extension from the vertebrae, secondary to downward extension of 
intracranial TBM or less commonly as a primary tuberculous lesion. In the fist case, 
tuberculous involvement of vertebral bodies known as Pott’s disease is established through 
either haematogenous spread of the bacillus or less frequently through spread from involved 
contiguous para-aortic lymph nodes. In case of extension of intracranial disease, the most 
usual mechanism is the rupture of a Rich’s focus into the spinal arachnoid space instead of the 
basal meninges (Dass et al., 2002; Garg, 1999; Harsha et al., 2006). 
5. Clinical features 
Tuberculosis of the central nervous system may take several forms, which cannot be easily 
classified (Table 1). Besides inflammation of the meninges, which is the most common form 
(Blaivas et al., 2005), it also includes space-occupying lesions in the brain parenchyma as 
well as focal disease of the spinal cord and its osseous structures.  
Intracranial central nervous system 
tuberculosis 
Tuberculous meningitis 
Tuberculous meningitis with miliary 
tuberculosis 
Tuberculous encephalopathy 
Tuberculous vasculopathy 
Central nervous system tuberculoma 
Tuberculous brain abscess 
Spinal central nervous system tuberculosis Pott’s spine and paraplegia 
Tuberculous arachnoiditis 
Non osseous spinal tuberculoma 
Spinal meningitis 
Table 1. Classification of central nervous system tuberculosis  
Each of these variable entities may represent a distinct subset of the central nervous system 
tuberculous infection or severe sequelae of TBM. Due to the significant overlap that exists 
between the clinical features of TBM and those of its complications, in this section besides 
TBM we will also emphasize on those manifestations that are part of its continuum, without 
differentiating them from the disease’s spectrum. 
5.1 Intracranial tuberculous meningitis  
TBM is characterized by a broad spectrum of manifestations, posing a diagnostic challenge 
and requiring a high index of clinical suspicion (Table 2). TBM tends to present subacutely, 
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over a period of variable duration that ranges in literature from weeks to months 
(Christensen et al., 2011; Komolafe et al., 2008; Newton, 1994) but in the majority of patients 
there is a history of vague non specific symptoms of a duration of two to eight weeks prior 
to meningeal irritation. These prodromal symptoms are constitutional and include malaise, 
fatigue, anorexia, fever and headache. According to studies, 75% of individuals have a 
tuberculous infection at least twelve months before admission for meningitis and 
radiological evidence of active pulmonary tuberculosis is present at a 30-50% of the cases 
upon admission (Cherian & Thomas, 2011; D’Souza et al., 2002). At the time of examination 
adults usually present with altered mental status ranging from lethargy to coma, meningeal 
symptoms and focal neurological signs but studies have demonstrated that meningeal 
stiffness may be absent in as many as three quarters and headache and fever in as many as 
25% of the patients (Christensen et al., 2011). In infants prodromal symptoms include 
irritability, drowsiness, poor feeding, and abdominal pain often associated with neck 
retraction and bulging fontanelles. As far as the elderly are concerned, headache and mental 
status changes are more common, on the other hand fever is frequently absent (Berger, 
1995). Atypical presentations include a rapid progression mimicking pyogenic meningitis, 
dementia, and a predominant syndrome of encephalitis with frequent convulsions occurring 
at any stage (Christie et al, 2008; Golden & Vikram, 2005). Cranial nerve palsies occur in 20-
30% of patients due to adhesions and may be the presenting manifestation of the disease or 
complicate its course. They most commonly involve cranial nerves II, III, IV, VI and VII, 
with VI being the one most commonly affected. Focal neurological deficits may also include 
hemiplegia, monoplegia and aphasia. Visual manifestations include visual impairment and 
opthalmoplegia and are attributed to optochiasmatic arachnoiditis, compression of optic 
chiasm in the setting of hydrocephalus, or optic nerve granulomas (Malik et al., 2002; Sinha 
et al., 2010). In case of tuberculomas or tuberculous brain abscess complicating meningitis 
the clinical features vary in accordance to their location. Tuberculous arachnoiditis is a rare 
complication of intracranial TBM, as a result of downward extension of the latter, that can 
lead to severe peripheral neurological deficit (Poon et al., 2003) often after an initial response 
to antituberculosis treatment, while syndrome of inappropriate antidiuretic hormone 
(SIADH) secretion is not an uncommon complication and is linked to a poor prognosis. As 
the inflammatory process progresses it might result in foci of encephalitis properly 
described as a diffuse meningoencephalitis with symptoms of cerebral disorder 
predominating and evolving from increasing lethargy to terminal illness coma (Drevets at 
al., 2004) 
5.2 Spinal tuberculous meningitis 
The clinical picture of spinal tuberculous meningitis is variable, depending on the stage of 
the disease and the mechanism involved in its pathogenesis. When secondary to a Rich’s 
focus rupture, it may present acutely with fever, headache, radiating root pain and 
myelopathy, or progress gradually with symptoms of spinal cord compression dominating 
the picture which may lead to misdiagnosis of an intradural tumor. The clinical spectrum 
may also include paradoxical reaction after initiating antituberculous therapy, spinal 
arachnoiditis, and simultaneous or preceding manifestations of TBM. If Pott’s disease is in 
the background, chronic manifestations of variable intensity reflecting the progressive 
destruction of the involved disc space and vertebral elements precede the meningeal 
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involvement and should guide the diagnosis. In such cases spinal meningitis is associated 
with focal tenderness over the spinous processes, focal kyphosis and cord compression 
phenomena, depending on the level of the spine that is affected (Garg, 1999; Harsha et al., 
2006; McLain & Isada, 2004). 
Symptoms Signs 
Headache 
Vomiting 
Low grade fever 
Lassitude 
Depression 
Confusion 
Behavioural changes 
Meningism  
Oculomotor palsies 
Papilloedema 
Depressed level of consciousness 
Focal hemisphere signs 
Table 2. Most common clinical features of tuberculous meningitis (adapted from Allen & 
Lueck, 2002)  
6. Staging 
TBM tends to be classified according to its severity at presentation in an attempt to assess 
prognosis. The Medical Research Council staging system has been applied since 1948 to 
patients with TBM and uses three stages of increasing severity. Stage I refers to alert patients 
without focal neurological signs, stage II to non comatose patients with altered 
consciousness and focal neurological deficits and stage III to comatose patients and those 
with multiple cranial nerve palsies and hemiplegia or/and paraplegia (Prasad & Singh, 
2008). Modifications of the above mentioned staging system have been adopted in recent 
literature (Heemskerk et al., 2011). The Acute Physiology and Chronic Health Evaluation II 
as well as the Glasgow Coma Scale have also been proposed for predicting the outcome of 
patients with TBM and are considered superior to the Medical Research Council scoring 
system by certain authors (Chou et al., 2010). Nevertheless, it is uniformly accepted that the 
stage of TBM at the onset of treatment seems to be the most crucial determinant of outcome, 
with mortality being highest if treatment started at Medical Research Council stage III. 
7. Differential diagnosis 
The diagnosis of TBM is challenging as it may mimic a wide range of medical conditions. 
It is generally based on clinical grounds and cerebrospinal fluid (CSF) examination (Table 
3). The differential diagnosis of the disease is particularly wide and at a clinical basis 
includes:  
1. Infections: bacterial (partially treated bacterial meningitis, brain abscess, listeriosis, 
Neisseria species infection, tularemia, brucellosis), spirochetal, viral (herpes, mumps, 
retrovirus, enterovirus), fungal (cryptococcal, histoplasmosis, actinomycetic, 
nocardiasis, candidiasis, coccidiosis) and parasitic (cysticercosis, acanthamoebiasis, 
strongyloidiasis, toxoplasmosis) 
2. Non infective conditions: vasculitis, systemic lupus erythematosus, neoplastic, 
chemical meningitis, cardiovascular, Behçet disease, acute hemorrhagic 
leukoencephalopathy etc. 
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CONDITION 
WHITE BLOOD 
CELLS 
PROTEIN GLUCOSE 
TBM Elevated, L > PMN Increased Decreased 
Cryptococcal 
meningitis 
Elevated, L > PMN Increased Decreased 
Partially treated 
bacterial meningitis 
Elevated Increased Decreased 
Viral meningitis Elevated, L > PMN Increased 
Normal or 
decreased  
Acute syphilis Elevated, L > PMN Increased Normal 
Late stage 
trypanosomiasis 
Elevated, L > PMN Increased Decreased 
Malignancy Elevated, L > PMN Increased Decreased 
Leptospirosis Elevated, L > PMN Increased Decreased 
Amoebic  Elevated, L > PMN Increased Decreased 
PMN: polymorphonuclear leucocytes, L: lymphocytes 
Table 3. Differential diagnosis of TBM based on CSF findings (adapted from Harries et al., 
2004)  
From a radiological point of view, taking into consideration the fact that bacterial 
meningitis, therefore TBM as well, is not an imaging diagnosis, such investigations are 
carried out in order to exclude the presence of other conditions mimicking meningitis and to 
detect possible contraindications for lumbar puncture such as increased intracranial 
pressure. Based on radiological findings the differential diagnosis of TBM also includes 
other infectious agents as well as non-infectious inflammatory diseases affecting the 
leptomeninges and neoplastic meningeal involvement (meningiomatosis, neoplastic 
meningitis from a peripheral tumor source etc.) (Junewick, 2010). 
8. Laboratory diagnosis  
Taking into consideration the fact that the high mortality rate associated with TB meningitis 
is related to its late diagnosis as well as the difficulties not only in obtaining a precise history 
but also in collecting an adequate volume of CSF for laboratory investigation, lumbar 
puncture and the examination of CSF are key points in its diagnosis.  
8.1 CSF parameters 
Examination of CSF in TBM usually reveals an increase in pressure with the fluid’s 
appearance ranging from clear to slightly turbid with, occasionally, a delicate web-like clot 
formation, due to the high protein level that is typical to the disease and a pleocytosis of 10–
1000 leucocytes/ mm3 with a lymphocytic predominance. The cell count rarely exceeds these 
values, on the contrary it is less than 500/ mm3 in the majority of cases. CSF biochemistry 
reveals reduced glucose levels, increased lactate levels, while protein levels are increased, 
especially in cases in which there is a CSF flow obstruction and which are associated with a 
worse prognosis. Early in the course of the disease a polymorphonuclear reaction as well as 
normal biochemical parameters might be found complicating the differential diagnosis, 
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particularly from bacterial meningitis. This polymorphonuclear predominance has been 
associated with a higher culture positivity and may even have a prognostic value, especially 
in HIV positive patients. In fact these patients occasionally exhibit a persistent 
polymorphonuclear predominance, which has been associated to higher survival rates, as it 
seems to have a protective role against M. tuberculosis (Hooker et al., 2003; Puccioni-Sohler & 
Brandão, 2007). For the performance of a total cell count of the CSF a fresh sample is loaded 
into an improved Neubauer chamber. A proportion of the fluid is centrifuged at 3000 g for 
15 min and from the sediment obtained, a Giemsa stained smear must be examined for the 
differential cell count (Christensen et al., 2011; Hooker et al., 2003; Kashyap et al., 2010; 
Puccioni-Sohler & Brandão, 2007; Ramachandran, 2011; Thwaites et al., 2004). 
8.2 Microscopy 
As far as the direct microscopy of a Ziehl-Neelsen stained smear is concerned, it should be 
conducted in all cases despite the low sensitivity of the examination attributed to the 
paucibacillary nature of the CSF. Each slide must be examined under the oil immersion lens 
for about 30 min, with care being taken to view at least 300–500 high power fields. It is 
proposed for each slide to be re-examined by an independent examiner to ensure accuracy. 
The sensitivity of the method ranges from 10-87% depending on the volume and the number 
of the samples and might drop to 2% after 5-15 days following the onset of treatment 
(Puccioni-Sohler & Brandão, 2007; Thwaites et al., 2004). The Ziehl-Neelsen stain remains an 
important diagnostic tool in tuberculosis since its first introduction in 1882 by Robert Koch 
as it identifies the most infectious cases, it is rapid, inexpensive, technically simple, and 
specific for AFB. However, it is unable to discriminate between M. tuberculosis and other 
mycobacteria, lacks sensitivity, and cannot be applied in the monitoring of treatment, as it 
does not discriminate between viable and non–viable bacilli. Its sensitivity appears to be 
lower in non-respiratory specimens due to the lower bacterial load as well as for some NTM 
species due to poorer staining of their cell wall (Mamoucha et al., 2010). 
8.3 Solid and liquid culture media 
Mycobacterial culture is the microbiological Gold Standard method for the confirmation of 
TBM as the isolation of M. tuberculosis from CSF makes a definite diagnosis of the disease, 
although in the setting of a strong clinical suspicion the isolation of the agent from other 
specimens such as gastric aspirate, bronchial aspirate, sputum or lymph node also guides 
the diagnosis (Kashyap et al., 2010; van Well et al., 2009). There is a variety of culture media 
used for this purpose. These include egg-based (Lövenstein-Jensen-LJ, Petragnani, American 
Trudeau Society, and Ogawa), agar-based (Middlebrook 7H10 and 7H11) and liquid media 
(Middlebrook 7H9, Kirchner, BioFM and Dubos). Due to the slow growth of the organism 
(40 to 60 days), this exam is useful only from an epidemiological point of view. In order to 
shorten the time of detection, Centers for Disease Control and Prevention (CDC) have 
recommended the use of liquid media for primary culture. Liquid culture medium has been 
designed to significantly reduce incubation time to 12-15 days and has been reported in 
various studies. Liquid TB culture media and Middlebrook 7H10 agar-based media, have 
been shown to increase the yield of TB particularly from body fluids but the highest 
recovery rate has been obtained using a combination of both (Fadzilah et al., 2009; Kashyap 
et al., 2010; Khosravi et al., 2009; Mamoucha et al., 2010; Panicker et al. 2010; 
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Piersimoni & Scarparo, 2008; Sorlozano et al., 2009). This may be attributed to the fact that in 
liquid cultures a mix of growth supplements (OADC- Oleic acid, Albumin, Dextrose, 
Catalase) and antibiotics (PANTA- Polymyxin B, Amphotericin B, Nalidixic acid, 
Trimethoprim, Azlocillin) are used, which collectively prevent the growth of environmental 
bacteria. According to literature, the isolation rate on MGIT 960 has been found 7.4% 
(Tortoli et al., 1999), 18.36% (Rishi et al., 2007) or 11.6% (Selvakumar et al., 1996), while using 
LJ medium the isolation rate has been found 4.3-6.5% (Rishi et al., 2007; Venkataswamy et 
al., 2007). Growth on the surface of the LJ slope is indicated by the production of raised, dry, 
cream coloured colonies while on Kirchner media by the formation of a surface pellicle, 
which should then be subjected to ZN stain and subcultured onto LJ slopes for confirmation 
and further identification (Hooker et al., 2003; Panicker et al., 2010). A positive result must 
be confirmed by performing a ZN smear of the colonies, with AFB being demonstrated. 
Furthermore, owing to the paucibacillary nature of cerebrospinal fluid, some authors 
propose filtration of the sample and inoculation of the residue on the culture media in order 
to increase the sensitivity of the method (Kumar et al., 2008).  
8.4 Adenosine deaminase levels and TBM 
Adenosine deaminase (ADA) is an enzyme involved in the purine catabolism by catalyzing 
the deamination of adenosine to inosine and of deoxyadenosine to deoxyinosine and is 
found in all tissues, particularly those of the lymphoid system. High ADA levels in 
tuberculosis are related to the activated T lymphocytes and macrophages in response to the 
tuberculous antigens (Blake & Berman, 1982) and in our laboratory their determination in 
pleural fluid has been routinely used as an aid in the establishment of tuberculous or 
nontuberculous aetiology of pleural effusion in variable clinical settings. As far as its role in 
the diagnostic approach of TBM is concerned, although still controversial, it is considered to 
be an inexpensive, simple and rapid method that could be used routinely following a 
lumbar puncture. On this basis certain methods have been developed for the determination 
of ADA activity with the Giusti-Galanti one being the most commonly used (Laniado-
Laborin, 2005; Oosthuizen et al., 1993). Moreover several studies have been conducted 
indicating that the ADA levels in CSF are higher in TBM than in nontuberculous meningitis. 
Depending on each study’s selected cutoff values the sensitivity and specificity for ADA 
have exhibited slight heterogeneity. In fact, CFS ADA cutoff value of 6.5 IU/L showed a 
sensitivity of 95.83% and a specificity of 92.85% (Baheti et al., 2001), while cutoff of 10 IU/L 
has been associated with a sensitivity and a specificity of 94.73% and 90.47% respectively 
(Gupta et al., 2010). However a meta-analysis study that was conducted recently in order to 
evaluate its diagnostic use concluded that ADA, irrespectively of the cutoff levels adopted, 
cannot distinguish between TBM and nontuberculous meningitis, but suggested that the use of 
ranges of its CFS values could have a role in improving TBM diagnosis, especially after 
bacterial meningitis has been excluded (Tuon et al., 2010). Thus the role of ADA activity 
determination in the diagnosis of TBM is still questionable by many scientists, with emphasis 
on the need of standardization of the methodology applied as well as of its cutoff values. 
Nevertheless, the enzyme’s levels are still considered as an additional diagnostic tool. 
8.5 Molecular diagnosis 
The need of a rapid diagnosis in the case of TBM has made the use of molecular techniques 
essential. Although the majority of commercial tests are licensed for nonrespiratory 
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specimens only, many of them have been in use along with in-house techniques and will be 
mentioned here, keeping in mind the fact that the data concerning their diagnostic value are 
based at large on the experience from studies emphasizing on respiratory samples. Even in 
such specimens, due to the need for further standardization between the different protocols 
and for implementation of solid guidelines concerning the evaluation of their results -
attributed to the methods’ innate disadvantages of practical nature as well as to the paucity 
of clinical data - their exact role remains controversial (Dora et al., 2008; Soini & Musser, 
2001). Nucleic acid-based amplification (NAA) tests allow the direct detection of 
mycobacterial DNA or RNA and they include both in-house and commercial tests with the 
latter being more standardized and therefore more reliable. Post-amplification analysis 
includes electrophoresis, hybridization, restriction or sequencing of the products with 
hybridization being the most commonly used one. The Amplified Mycobacterium tuberculosis 
Direct Test (AMTD2, Gen-Probe, bioMerieux, Marcy, L’Etoile, France) which is based on the 
amplification of a Mycobacterium tuberculosis specific region of 16S rRNA using a reverse 
transcriptase was the first one to be approved by the Food and Drug Administration (FDA) 
in 1995, with its recommendations also including extrapulmonary samples, followed by the 
Amplicor M. tuberculosis test (Roche Diagnostic System Inc., Basel Switzerland) in 1996, 
which targets a segment of the same gene with the use of standard polymerase chain 
reaction (PCR). Other methods described include the BD ProbeTec ET Direct TB System 
(DTB, Becton Dickinson) which is a strand displacement amplification method targeting the 
IS6110 and 16S genes, the GenoType Mycobacteria Direct (Hain LifeScience, Nahren, 
Germany) and the INNO-LiPA Rif. TB kit (Innogenetics, Gent, Belgium), both using nucleic 
acid sequenced based amplification (NASBA) and offering the advantage of detecting not 
only members of the M. tuberculosis complex but certain common NTM as well. Newer 
techniques based on real-time PCR amplify simultaneously different DNA targets followed 
by fluorimetric detection and are considered promising. Among them the 
GeneXpertMTB/RIF (Cepheid, Summyvale, CA, USA and FIND Diagnostics, Geneva, 
Switzerland), which also offers the possibility for detection of RIF resistance, has recently 
been approved by the WHO (Alcaide & Coll, 2011; Dora et al., 2008; Soini & Musser, 2001). 
On the other hand, the in-house techniques use the PCR in order to amplify specific regions 
of Mycobacterium tuberculosis genome varying from one institution to another, with the 
IS6110 (Insertion sequence 6110) element and devR element (Haldar et al., 2009; Michael et 
al., 2002) being the ones most commonly used. Reported results of the molecular tests in CSF 
specimens vary in different studies with reported sensitivity and specificity ranging from 
50%-87.6% and 92%-98.6% respectively (Dora et al., 2008; Haldar et al., 2009; Pai et al., 2003). 
This low sensitivity could be attributed to the volume of the sample, given the lower 
number of bacteria usually found in the CSF compared to other compartments, therefore the 
minimum suggested volume of the fluid is 2ml (Michael et al., 2002). In conclusion both 
commercial and in-house molecular techniques might have a role in confirming TBM, 
although their low sensitivity doesn’t seem to allow them to exclude it with certainty. 
9. Treatment of TBM 
The most important determinant of TBM’s prognosis is the stage of the disease at the time of 
initiation of appropriate treatment with evidence indicating that timely onset during the 
early phase of infection can significantly improve the outcome. Therefore, any patient 
suspected of having TBM based on the clinical symptoms and - when present - signs of 
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increased intracranial pressure as well as CSF findings compatible with the disease should 
be started on anti-tuberculous chemotherapy without awaiting for the CSF laboratory 
results. The recommended first line treatment agents for all forms of CNS tuberculosis 
administered daily either individually or in a combination form are isoniazid (INH), 
rifampicin (RIF), pyrazinamide (PZA), streptomycin (SM), and ethambutol. Second-line 
therapy includes ethionamide, cycloserine, para-aminosalicylic acid (PAS), aminoglycosides, 
capreomycin, thiacetazone, while potential new agents include oxazolidinone, isepamicin 
and a new rifamycin called rifapentine. Fluoroquinolones that have a role in the treatment of 
TBM include ciprofloxacin, ofloxacin, and levofloxacin. Finally, because of the intensity of 
the inflammatory and fibrotic reactions at the meningeal site, adjunctive corticosteroids, in 
addition to standard antituberculous therapy, are recommended (Girgis et al., 1998; 
Ramachandran, 2011). Taking into consideration the fact that the same regimens are 
recommended for the treatment of pulmonary and extrapulmonary disease, isoniazid, 
rifampicin and pyrazinamide are considered mandatory at the beginning of TBM treatment 
and some centers use all three for the whole duration of therapy. There are no data from 
controlled trials to guide the choice of the fourth drug. Most authorities recommend either 
streptomycin or ethambutol, although neither penetrates the CSF in a satisfactory degree in 
the absence of inflammation, and both can produce significant adverse reactions. According 
to the guidelines recommended by the World Health Organisation (WHO) however, 
ethambutol should be replaced by streptomycin (Thwaites et al., 2009; WHO, 2010). The 
duration of therapy in tuberculous meningitis is controversial with considerable variation in 
recommendations by different expert groups on this issue (Prasad & Sahu, 2010). Some 
experts recommend 9-12 months of treatment for TB meningitis given the serious risk of 
disability and mortality (WHO, 2010). The Indian Academy of Paediatrics (Indian Academy 
of Paediatrics [IAP], 2011) recommends that the continuation phase of treatment in TB 
meningitis should last for 6-7 months, extending the total duration of treatment to 8-9 
months. The recommended by the British Infection Society (Thwaites et al., 2009) first line 
treatment regimen for all forms of CNS tuberculosis is given in Table 4. 
Drug 
Daily dose 
Route Duration 
Children Adults 
Isoniazid 
10-20mg/kg  
(max 500mg) 
300mg oral 12 months 
Rifampicin 
10-20mg/kg  
(max 600mg) 
450mg (<50 mg) 
oral 12 months 
600mg (≥50 mg) 
Pyrazinamide 30-35mg/kg (max 2g) 
1.5g (<50 mg) 
oral 2 months 
2.0g (≥50 mg) 
Ethambutol 15-20mg/kg (max 1g) 15 mg/kg oral 2 months 
Table 4. Recommended treatment regimen for CNS tuberculosis caused by fully susceptible 
M. tuberculosis (adapted from Thwaites et al., 2009) 
Among the bactericidal agents INH, RIF, and PZA, isoniazid has the best CSF 
pharmacokinetics with concentrations (Cmax), being only slightly less than in blood 
(Donald, 2010). It penetrates the CSF freely, has potent early bactericidal activity and at 
standard dosages it achieves CSF levels of 10-15 times the minimum inhibitory 
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concentration of M. tuberculosis. Its main disadvantage is that resistance develops quite 
quickly when used as a monotherapy though this does not seem to happen when it is used 
for chemoprophylaxis (Cherian & Thomas, 2011). PZA also exhibits a good CSF penetration 
and in children receiving appropriate dosages the achieved Cmax exceeds the proposed 
minimal inhibitory concentration of 20 μg/ml. In this patient group rifampicin is more 
successful in reaching CSF concentrations above its minimum inhibitory concentration than 
in adult adjusted dosages but it can achieve optimal levels only when the meninges are 
inflamed. Streptomycin, other aminoglycosides and ethambutol have a poor CSF 
penetration and cannot be administered as first line agents (Ramachandran, 2011). Among 
the second line agents ethionamide, fluoroquinolones, with the exception of ciprofloxacin, 
and cycloserine display a relatively good CSF penetration and can be administered in TBM 
(Donald, 2010). 
9.1 Use of steroids in TBM 
The British Infection Society recommends that all patients with TBM should receive 
adjunctive corticosteroids regardless of disease severity at presentation. The value of 
adjuvant corticosteroids lies in reducing the harmful effects of inflammation while 
antibiotics kill the organisms and studies have demonstrated significant decrease in 
mortality and morbidity of patients receiving dexamethasone compared with those not 
receiving it (Girgis et al., 1998; Ramachandran, 2011; Thwaites et al., 2009). 
9.2 Treatment of TBM and HIV infection 
Determination of HIV status is mandatory in all patients with suspected CNS TB not only 
because TB may be the first indication of an underlying HIV infection and because of the 
increased frequency of extrapulmonary involvement in persons with immunosuppression, 
but also due to the impact that TB might have on the antiretroviral (ART) treatment 
decisions. In case of a positive HIV status the choice and duration of anti-TB therapy 
remains unaltered and patients should receive the drug regimen that is recommended for 
HIV negative individuals with rifampicin being administered when possible, taking into 
consideration the fact that this agent induces the metabolism of the protease inhibitors, 
delavirdine and nevirapine reducing their levels (Thwaites et al., 2009). According to WHO 
the recommended first line ART regimens for TB patients are those that contain efavirenz 
(EFV) since its interactions with anti-TB drugs are minimal. In individuals who require an 
ART regimen containing a boosted protease inhibitor (PI), it is recommended to give a 
rifabutin based TB treatment. If rifabutin is not available, the use of rifampicin and a 
boosted antiretroviral regimen containing lopinavir or saquinavir with additional ritonavir 
dosing is recommended but this regimen should be closely monitored. Adjunctive 
corticosteroids are also recommended (Cherian & Thomas, 2011; WHO, 2010).  
9.3 Treatment of multi-drug resistant TBM 
Despite the fact that multi-drug resistant (MDR) tuberculous meningitis is at present a 
worldwide reality, in contrast to MDR pulmonary TB, it has not been well described, with 
the exception of limited reports (Byrd & Davis, 2007; Daicos et al., 2003; Schutte, 2001). The 
low sensitivity of CSF smears and culture as well as the prolonged time required for 
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culturing and susceptibility testing, which underestimate its true incidence, have 
contributed to this. The emergence of multi-drug resistant TB meningitis complicates the 
management of the disease, because the first line anti-TB regimen is inadequate. Second line 
agents with the exception of ethionamide, cross the blood-brain barrier poorly, resulting in 
suboptimal concentrations in CSF and since there are not enough pharmacokinetic data for 
drugs such as cycloserine and thiacetazone, the management of CNS disease caused by 
bacilli resistant to both INH and RIF is challenging (Daicos et al., 2003; Patel et al., 2004). 
Suspected isoniazid resistant disease, without rifampicin resistance, should be treated 
initially with conventional 4-drug first line therapy. If a low level resistance is proven or the 
cultures are uninformative, the British Infection Society recommends 12 months of 
treatment including rifampicin, isoniazid, and pyrazinamide and ethambutol, the latter 
being discontinued after 2 months. If a high level isoniazid resistance is proven, exchanging 
the agent for levofloxacin or moxifloxacin for at least 12 months in combination with 
rifampicin and pyrazinamide is recommended. For patients with suspected or proven MDR 
CNS tuberculosis the British Infection Society recommends initial therapy with at least a 
fluoroquinolone, pyrazinamide, ethionamide or prothionamide, and amikacin or 
capreomycin, unless there is resistance to any of these agents (Thwaites et al., 2009). The 
standard treatment regimens, which are designed according to the general principles of the 
therapeutic approach to MDR TB, should be changed to individualized ones once the results 
on drug susceptibility concerning other agents besides INH and PZA are available (WHO, 
2010). As far as paediatric groups are concerned, further studies of the sensitivity patterns 
are required in order to standardise and optimise the second line treatment protocols 
(Padayatci et al., 2006). 
9.4 Neurosurgery 
Besides its diagnostic value and although it is used in the management of the late 
complications of the disease, neurosurgery plays a minor role in the treatment of TBM. 
Hydrocephalus, tuberculous brain abscess (TBA), and vertebral tuberculosis with cord 
compression, may be indications for urgent neurosurgical intervention, even though early 
hydrocephalus and tuberculous brain abscess can be successfully treated by drugs alone. So 
early recognition and timely treatment is critical in avoiding the surgery. The aim of surgical 
management of TBA is to reduce the size of the space-occupying lesion and subsequently 
diminish intracranial pressure. Anti-TB therapy prior to the surgery is considered 
mandatory and appears to reduce the risk of postoperative meningitis. Urgent surgical 
decompression should also be considered in all the cases with extradural lesions causing 
paraparesis (Cherian & Thomas, 2011). 
10. Conclusion 
Tuberculosis is a serious public health issue with tuberculous meningitis being the most 
severe extrapulmonary form as well as the most common manifestation of central nervous 
system disease. The causative agents are members of M. tuberculosis complex and NTM, 
which should be strongly considered as important CNS pathogens in patients with HIV 
infection. The three most commonly used laboratory methods of TBM diagnostics are smear 
microscopy, culture and molecular techniques but as the stage of the disease at the time of 
treatment onset is the most important determinant of prognosis, anti-TB therapy should be 
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initiated even before their completion. Nevertheless, the disease’s wide clinical spectrum 
combined with the significant overlap between its syndromes pose a diagnostic challenge, 
underlining the importance of a high index of clinical suspicion. We should keep in mind 
that rapid diagnosis of TBM besides its impact in the disease’s outcome is also central to 
controlling primary tuberculosis, especially in the wake of the emergence of multi-drug 
resistant TB and its severe implications particularly for HIV infected patients.  
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